Hospira finishes for Genzyme

Genzyme has tapped Hospira for fill and finish of Cerezyme and Fabrazyme, helping to alleviate shortages of two key drugs. The Boston-based big biotech is still struggling to get its Allston Landing plant up to full compliance following last summer's shutdown. Report

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.